Avanos Medical, INC

Avanos Medical, Inc. announced that its stockholders have approved the pending acquisition by affiliates of American Industrial Partners (AIP) at a special meeting.

Avanos Medical announced it has received all necessary regulatory approvals for its pending acquisition by American Industrial Partners, moving closer to closing the deal.

Avanos Medical announced first quarter 2026 financial results, showing an 8.8% increase in total net sales driven by its Specialty Nutrition Systems segment, while also noting the pending acquisition by American Industrial Partners.

Avanos Medical, Inc. has entered into a definitive agreement to be acquired by American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.272 billion.

Avanos Medical, Inc. has entered into a cooperation agreement with activist investor Bradley L. Radoff, leading to the nomination of James L. Cunniff and William P. Burke as independent directors to its Board.

Avanos Medical, Inc. reported strong fourth quarter and full-year 2025 results, exceeding full-year revenue guidance and achieving the top end of EPS guidance, driven by strategic segment growth and cost management.

Avanos Medical's Q1 2026 results show a revenue increase driven by Specialty Nutrition Systems, while facing challenges in Pain Management and Recovery, all under the shadow of a pending acquisition by American Industrial Partners.

Avanos Medical, Inc. reported a significant net loss for the nine months ended September 30, 2025, driven by a $77.0 million goodwill impairment and increased restructuring costs, despite modest net sales growth.

Avanos Medical, Inc. reported a significant net loss for the second quarter of 2025, primarily driven by a $77.0 million goodwill impairment charge related to its Pain Management and Recovery segment, despite modest revenue growth.

Avanos Medical's first quarter 2025 results show a slight increase in net sales and ongoing restructuring efforts to align with the company's strategic focus.

Avanos Medical's third-quarter results show a slight decrease in net sales, offset by improvements in operating profit, as the company continues its restructuring and transformation initiatives.

Avanos Medical's second quarter results show a slight increase in net sales and a return to operating profit, while the company continues its restructuring and transformation initiatives.

Avanos Medical, Inc. reported a significantly reduced net loss in 2025, driven by strategic acquisitions and divestitures, despite ongoing restructuring costs and a goodwill impairment.

Avanos Medical's 2024 Form 10-K reveals substantial goodwill and intangible asset impairments, impacting operating results despite a slight increase in net sales.

Avanos Medical Inc. has released its 2023 annual report, outlining financial results, strategic shifts, and ongoing restructuring efforts.

Sigfrido Delgado, SVP, Operations of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.

Scott Michael Galovan, SVP, Chief Financial Officer of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.

David Pacitti, Chief Executive Officer of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.

Julie Ann Shimer, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.

Patrick J Oleary, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.

Indrani Lall Franchini, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.

Avanos Medical, Inc. announces its 2026 Annual Meeting of Stockholders to address director elections, auditor ratification, executive compensation, and an amendment to its long-term incentive plan.

Avanos Medical, Inc. is holding its 2025 Annual Meeting of Stockholders on April 24, 2025, and provides information on how to vote on key proposals.

Avanos Medical is asking stockholders to approve an amendment to its 2021 Long Term Incentive Plan to increase the number of shares available for issuance by 2,250,000 at the upcoming annual meeting.

Avanos Medical, Inc. announces its 2024 Annual Meeting of Stockholders to be held on April 25, 2024, and provides information on accessing proxy materials and voting.

Avanos Medical has set the date for its 2024 Annual Meeting of Stockholders on April 25, 2024, and released related proxy materials.

Vanguard Capital Management has reported beneficial ownership of 5% of Avanos Medical Inc.'s common stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 4.3% of Avanos Medical, Inc. common stock as of March 31, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 3.7% of Avanos Medical Inc.'s common stock as of April 30, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 11.5% of Avanos Medical Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Avanos Medical Inc. following an internal realignment, marking a complete divestment of its previously reportable stake.

RGM Capital, LLC and Robert G. Moses report 0% beneficial ownership of Avanos Medical, Inc. common stock in their latest Schedule 13G amendment.